Long-acting platform Hera offers a biodegradable, long-acting drug delivery platform capable of sustaining effects up to 48 months, presenting opportunities to partner with pharma companies seeking to extend dosing intervals and improve patient adherence.

Asia expansion Recent licensing expansion into Asia via Geovista indicates an international growth trajectory and potential co-development or regional manufacturing collaborations to serve Asian markets.

Arab Health win Winning the Arab Health Innov8 competition with a cash prize signals strong validation, credibility, and potential for introductions to prospective customers and partners in global healthcare ecosystems.

SBIR backing NSF SBIR funding underscores credible R&D validation and government-supported innovation, which can be leveraged to de-risk partnerships and attract customers seeking technically solid long-acting delivery solutions.

Financial potential Current revenue range and a small team profile suggest a nimble partner open to collaboration and licensing deals; target mid-to-large pharma players seeking scalable, plug‑and‑play delivery platforms to accelerate APIs into long-acting formats.